1. Market Research
  2. > Biotechnology Market Trends
  3. > Biotechnology Analysis & Statistics 2020 - United Kingdom

Biotechnology Analysis & Statistics 2020 - United Kingdom

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Firstword Pharma

All regions

1-9 of 9 reports

Rheumatoid Arthritis: KOL Insight [2018]

  • $ 9000
  • March 2018
  • 1 pages

How is Olumiant impacting the RA treatment landscape? After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, Eli Lilly/Incyte’s ...

  • Biotechnology
  • Health Services
  • Medical Biotechnology
  • United Kingdom
  • United States

Targeted Therapies in Asthma: KOL Insight [2018]

  • $ 9000
  • February 2018
  • 1 pages

Can new biologics breathe fresh competition into the targeted asthma treatment landscape? The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved ...

  • Asthma
  • Biotechnology
  • Medical Biotechnology
  • Therapy
  • United Kingdom

Market Access Impact (EU5) [RA]

  • $ 5637
  • November 2017
  • 1 pages

Eliminating market barriers could help one brand almost double its market share Market barriers have a modest but significant effect on rheumatoid arthritis (RA) prescriptions in the EU5. The brands that ...

  • Medical Biotechnology
  • United Kingdom
  • Market Shares

Systemic Lupus Erythematosus (SLE): KOL Insight 2017

  • $ 8658
  • July 2017
  • 1 pages

Will novel therapies revolutionise the treatment of SLE? With the approval of GSK’s Benlysta (belimumab) came the dawn of targeted therapy in the treatment of systemic lupus erythematosus (SLE). Roche’s ...

  • Biotechnology
  • Medical Biotechnology
  • Therapy
  • United Kingdom
  • United States

Rheumatoid Arthritis [2017]

  • $ 8658
  • April 2017
  • 1 pages

How are biosimilar anti-TNFs faring? Will your brand be affected? After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, it now ...

  • Biotechnology
  • Medical Biotechnology
  • European Union
  • United Kingdom
  • United States

HNSCC: KOL Insight - 2017

  • $ 8658
  • March 2017
  • 1 pages

Description How will immunotherapy continue to shape the HNSCC treatment landscape? The availability of Merck &Co.’s Keytruda and BMS’ Opdivo has already transformed the second-line treatment of head ...

  • Biotechnology
  • Medical Biotechnology
  • Therapy
  • United Kingdom
  • United States

Medical Affairs Reputations: Rheumatoid Arthritis (EU) 2016

  • $ 6755
  • October 2016
  • 1 pages

Does your medical affairs team need a wakeup call? Our survey results say yes. In the rheumatoid arthritis (RA) market, not even the leading medical affairs teams are doing a great job of delivering the ...

  • Health Services
  • Medical Biotechnology
  • United Kingdom

Cancer Immunotherapy: Update Bulletin [March 2016]

  • $ 1077
  • March 2016
  • 1 pages

In this update, payers offer their views on the recent reform of the cancer drugs fund (CDF) and its impact on access to cancer immunotherapies in the UK. In light of the impressive data recently released ...

  • Biotechnology
  • Cancer Immunotherapy
  • Immunotherapy
  • Therapy
  • United Kingdom

Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders

  • $ 7638
  • February 2015
  • 1 pages

Based on survey results from 150 rheumatologists, dermatologists, and gastroenterologists in UK, France, Germany, Spain and Italy, Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory ...

  • Biosimilar
  • Biotechnology
  • Medical Biotechnology
  • Monoclonal Antibody
  • United Kingdom



Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on